Tags

Type your tag names separated by a space and hit enter

Hepatotoxicity of thiazolidinediones.
Expert Opin Drug Saf 2003; 2(6):581-6EO

Abstract

Thiazolidinediones are insulin sensitisers now widely used for the treatment of Type 2 diabetes mellitus. The initial marketed drug in this class, troglitazone, was removed from the market worldwide after approximately 3 years of use due to rare but severe hepatotoxicity, which sometimes resulted in liver failure leading to the need for liver transplantation, or even death. The unpredictability of such liver toxicity made the use of troglitazone highly problematic. Fortunately, the two newer drugs in this class, rosiglitazone and pioglitazone, have a much larger margin of safety for liver toxicity. Very rare reports of liver toxicity, usually milder and reversible, have been seen with these drugs. Therefore, whilst pharmacovigilance for hepatotoxicity is probably still warranted, the practitioner and patient can be fairly confident that these drugs are safe from a liver standpoint. Finally, recent work would suggest that these agents may prove useful to reduce hepatic fat in patients with non-alcoholic steatohepatitis, and may possibly protect against adverse metabolic consequences and the ultimate development of cirrhosis in patients with fatty livers.

Authors+Show Affiliations

Mayo Clinic, W18A, 200 First Street SW, Rochester, MN 55905, USA. Isley.William@mayo.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14585066

Citation

Isley, William L.. "Hepatotoxicity of Thiazolidinediones." Expert Opinion On Drug Safety, vol. 2, no. 6, 2003, pp. 581-6.
Isley WL. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf. 2003;2(6):581-6.
Isley, W. L. (2003). Hepatotoxicity of thiazolidinediones. Expert Opinion On Drug Safety, 2(6), pp. 581-6.
Isley WL. Hepatotoxicity of Thiazolidinediones. Expert Opin Drug Saf. 2003;2(6):581-6. PubMed PMID: 14585066.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hepatotoxicity of thiazolidinediones. A1 - Isley,William L, PY - 2003/10/31/pubmed PY - 2004/4/8/medline PY - 2003/10/31/entrez SP - 581 EP - 6 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 2 IS - 6 N2 - Thiazolidinediones are insulin sensitisers now widely used for the treatment of Type 2 diabetes mellitus. The initial marketed drug in this class, troglitazone, was removed from the market worldwide after approximately 3 years of use due to rare but severe hepatotoxicity, which sometimes resulted in liver failure leading to the need for liver transplantation, or even death. The unpredictability of such liver toxicity made the use of troglitazone highly problematic. Fortunately, the two newer drugs in this class, rosiglitazone and pioglitazone, have a much larger margin of safety for liver toxicity. Very rare reports of liver toxicity, usually milder and reversible, have been seen with these drugs. Therefore, whilst pharmacovigilance for hepatotoxicity is probably still warranted, the practitioner and patient can be fairly confident that these drugs are safe from a liver standpoint. Finally, recent work would suggest that these agents may prove useful to reduce hepatic fat in patients with non-alcoholic steatohepatitis, and may possibly protect against adverse metabolic consequences and the ultimate development of cirrhosis in patients with fatty livers. SN - 1474-0338 UR - https://www.unboundmedicine.com/medline/citation/14585066/Hepatotoxicity_of_thiazolidinediones_ L2 - http://www.tandfonline.com/doi/full/10.1517/14740338.2.6.581 DB - PRIME DP - Unbound Medicine ER -